MZL stands for marginal zone lymphoma, an indolent B-cell non-Hodgkin lymphoma with extranodal, nodal, and splenic forms. It usually has a slow clinical course but may require treatment based on symptoms and disease burden.
The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07492407 |
CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma |
NOT_YET_RECRUITING | |
| NCT07459608 |
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07259070 |
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06510309 |
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma |
RECRUITING | PHASE2 |
| NCT05176691 |
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL |
WITHDRAWN | PHASE1 |
| NCT03846427 |
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma |
COMPLETED | PHASE2 |
| NCT03797456 |
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) |
COMPLETED | PHASE2 |
